Sotyktu (deucravacitinib) - (POETYK PsA-2)

September 15, 2026: Bristol Myers Squibb (NYSE: BMY) reported positive 2-year Phase 3 POETYK PsA-2 open-label extension data for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis, to be presented at CCR-West in Huntington Beach, California, September 17-20, 2026.

In patients treated continuously with Sotyktu from the start of the Phase 3 study through the OLE, Week 104 ACR20/50/70 response rates were 76.2%/52.6%/34.6% by observed analysis and 65.3%/44.9%/29.4% with nonresponder imputation; minimal disease activity rates were 51.2% observed and 43.7% by NRI. In patients who switched from placebo to Sotyktu at Week 16, Week 104 ACR20/50/70 rates were 76.9%/54.6%/37.7% observed and 69.3%/49.2%/33.9% by NRI; MDA rates were 48.7% observed and 43.7% by NRI.

The company said responses improved from Week 16 to Week 52 and were maintained through Week 104. Safety through Week 104 was consistent with prior results, with no new safety signals. Across 604 patients with any Sotyktu exposure over 2 years, adverse events occurred in 86.6%, serious AEs in 12.6%, and discontinuations due to AEs in 7.6%; common AEs were upper respiratory tract infection, nasopharyngitis, and COVID-19. Results from the POETYK PsA-1 OLE will be presented at a future medical meeting.